OS promise for 177Lu-dotatate in neuroendocrine tumors
medwireNews: A prespecified interim analysis of the NETTER-1 trial suggests that treatment with lutetium-177 (177Lu)–dotatate could prolong overall survival (OS) relative to high-dose octreotide long-acting repeatable (LAR) in patients with metastatic midgut neuroendocrine tumors.
The investigators previously reported that the primary endpoint of progression-free survival (PFS) was significantly improved with 177Lu-dotatate versus octreotide LAR in this patient population, all of whom had progressed on prior somatostatin analog (low-dose octreotide LAR) therapy.
Now they also report the interim OS findings, which show that the risk for death was a significant 60% lower for the 116 participants randomly assigned to receive four doses of intravenous 177Lu-dotatate (7.4 GBq) every 8 weeks plus intramuscular octreotide 30 mg monthly than for their 113 counterparts given octreotide 60 mg every 4 weeks.
Data were not sufficiently mature to estimate the median OS times in either group at this timepoint, say Jonathan Strosberg (Moffitt Cancer Center, Tampa, Florida, USA) and colleagues in The New England Journal of Medicine, but “the results of the interim analysis suggest longer overall survival with 177Lu-Dotatate than with high-dose octreotide LAR.”
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2017